---
title: "Supporting Market Access to Essential Medicines in Europe"
description: "Support your entry into the European pharmaceutical market with expert regulatory guidance, ensuring compliance and access to essential medicines for patients. Contact us today for assistance."
url: https://qbdgroup.com/en/case-studies/supporting-market-access-to-essential-medicines-in-europe
type: "Case study"
language: en
published: 2025-03-05
publisher: "QbD Group"
citation: "QbD Group, \"Supporting Market Access to Essential Medicines in Europe\", https://qbdgroup.com/en/case-studies/supporting-market-access-to-essential-medicines-in-europe"
---
# Supporting Market Access to Essential Medicines in Europe
> Support your entry into the European pharmaceutical market with expert regulatory guidance, ensuring compliance and access to essential medicines for patients. Contact us today for assistance.

Our client is a **leading pharmaceutical manufacturer** in Asia, **specializing in anesthetics, analgesics, and narcotics**. With a strong presence in global markets, the company aimed to introduce a key product to Europe where access to similar treatments remains limited. **However, entering the European market required navigating complex regulatory requirements, including obtaining an EU GMP license** to ensure compliance with stringent quality and safety standards.

## Challenge

### Regulatory & compliance challenges

To bring their product to European patients, the company needed to secure an EU GMP license, conduct audits to demonstrate compliance, and establish a solid regulatory strategy.

In addition, they were responsible for compiling and submitting a complete dossier, managing communication with regulatory authorities, and implementing laboratory method transfer to support retesting and Qualified Person (QP) batch release.

## Approach

QbD Group provided comprehensive regulatory and quality support to to guide the company toward market entry. Our approach included:

- Conducting audits at the API and finished product manufacturing sites to support the **QP declaration**.
- Developing a robust **regulatory strategy**, compiling the **Common Technical Document (CTD) and eCTD for submission**.
- Managing communication with regulatory authorities and addressing deficiency letters to streamline approval.
- Facilitating laboratory **method transfer** to ensure smooth retesting and **QP batch release** processes.

## Result

### Progressing toward market authorization

While the project is still ongoing, significant milestones have been achieved:

- Submission of key regulatory documentation to support the EU GMP licensing process.
- Active engagement with competent authorities to address regulatory feedback and refine submission materials.
- Future **pharmacovigilance support** planned to ensure ongoing compliance and patient safety.

The ultimate goal remains securing timely **Market Authorization Approval** enabling the company to introduce its product in Europe and expand patient access to essential treatments.
---
Source: https://qbdgroup.com/en/case-studies/supporting-market-access-to-essential-medicines-in-europe — © QbD Group. Quote freely with attribution and a link back.